A Phase 3 interventional study of Pneumococcal conjugate vaccine GSK1024850A and Prevenar in Hepatitis B, Acellular Pertussis and Tetanus, sponsored by GlaxoSmithKline. Completed at 63 sites in 3 countries. Open to participants aged 11 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-02.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.
Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one has the largest enrollment, is one of 2 that started in 2007, is one of 7 in phase 3, and was the 4th registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 11 Months to 18 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2007.
This study's enrollment of 1,437 is above the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 417 across the 16 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
144 studies in Hepatitis B by GlaxoSmithKline: 2 open now, 6 under way, none of them phase 3. Of 136 finished, 69 (51%) have results posted.
Among the 144 studies in Hepatitis B by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 137 interventional ones that give a count, is one of 5 that started in 2007, is one of 56 in phase 3, and was the 48th registered.
GlaxoSmithKline’s Hepatitis B studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 144 in Hepatitis B:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK1024850A at 11 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined and meningococcal serogroup C (MenC) or combined meningococcal serogroup C and Haemophilus influenzae type b (Hib-MenC) vaccine.
This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334).
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa · Biological: Infanrix IPV Hib · Biological: Meningitec
Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa · Biological: Infanrix IPV Hib · Biological: NeisVac-C
Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix penta · Biological: Infanrix IPV · Biological: Menitorix
Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
Biological: Prevenar · Biological: Infanrix penta · Biological: Infanrix IPV · Biological: Menitorix
Intramuscular injection, 1 dose.
Intramuscular injection, 1 dose.
Also known as: Pneumococcal conjugate vaccine (Wyeth Lederle).
Intramuscular injection, 1 dose. In Germany and Poland.
Also known as: DTPa-HBV-IPV/Hib (GSK Biologicals).
Intramuscular injection, 1 dose. In Spain.
Also known as: DTPa-IPV/Hib (GSK Biologicals).
Intramuscular injection, 1 dose. In Germany and Poland.
Also known as: DTPa-HBV-IPV (GSK Biologicals).
Intramuscular injection, 1 dose. In Spain.
Also known as: DTPa-IPV (GSK Biologicals)
Intramuscular injection, 1 dose.
Also known as: Meningococcal C conjugate vaccine (Wyeth).
Intramuscular injection, 1 dose.
Also known as: Meningococcal C conjugate vaccine (Baxter).
Intramuscular injection, 1 dose.
Also known as: Combined Hib-MenC vaccine (GSK Biologicals).
Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)
Fever was measured as rectal temperature.
Time frame: During the 4-day (Day 0-3) period after the booster vaccination
Number of Subjects Reporting Solicited Local Symptoms
Solicited local symptoms assessed include pain, redness and swelling.
Time frame: During the 4-day (Day 0-3) period after the booster vaccination
Number of Subjects Reporting Solicited General Symptoms
Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.
Time frame: During the 4-day (Day 0-3) period after the booster vaccination
Number of Subjects Reporting Unsolicited Adverse Events (AE)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: During the 31-day (Day 0-30) period after the booster vaccination
Number of Subjects Reporting Serious Adverse Events (SAE)
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
Time frame: During the 31-day (Day 0-30) period after the booster vaccination
Number of Subjects Reporting Serious Adverse Events (SAE)
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
Time frame: From the beginning of the study up to the end of the extended 6-month safety follow-up period
Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value
Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value
Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value
Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value
Anti-pneumococcal antibody cut-off value assessed was ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value
Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value
Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value
Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.
Time frame: Before (pre) and one month after (post) the booster administration
Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value
Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.
Time frame: Before (pre) and one month after (post) the booster administration
| Milestone | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Started | 359 | 363 | 358 | 357 |
| Completed | 355 | 352 | 352 | 350 |
| Not completed | 4 | 11 | 6 | 7 |
Fever was measured as rectal temperature.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C) | — | — | 11 | 8 |
Solicited local symptoms assessed include pain, redness and swelling.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Pain | 196 | 195 | 193 | 165 |
| Redness | 194 | 183 | 186 | 173 |
| Swelling | 162 | 148 | 150 | 134 |
Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Drowsiness | 124 | 142 | 139 | 105 |
| Fever (≥ 38.0 °C) | 109 | 122 | 105 | 108 |
| Irritability | 170 | 190 | 191 | 157 |
| Loss of appetite | 101 | 99 | 112 | 93 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AE) | 59 | 74 | 59 | 76 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAE) | 3 | 5 | 3 | 2 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAE) | 15 | 9 | 13 | 13 |
Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Anti-1 pre (n=150,152,149, 151) | 146 | 146 | 140 | 21 |
| Anti-1 post (n=158,152,160,151) | 158 | 152 | 160 | 28 |
| Anti-4 pre (n=153,156,150,153) | 152 | 156 | 147 | 150 |
| Anti-4 post (n=158,153,160,152) | 158 | 153 | 160 | 152 |
| Anti-5 pre (n=149,146,146,148) | 149 | 146 | 144 | 37 |
| Anti-5 post (n=157,153,160,150) | 157 | 153 | 160 | 64 |
| Anti-6B pre (n=151,155,150,151) | 149 | 153 | 144 | 137 |
| Anti-6B post (n=158,153,160,153) | 157 | 151 | 158 | 153 |
| Anti-7F pre (n=149,153,148,151) | 149 | 153 | 147 | 18 |
| Anti-7F post (n=158,152,160,151) | 158 | 152 | 160 | 25 |
| Anti-9V pre (n=149,155,149,152) | 149 | 154 | 149 | 152 |
| Anti-9V post (n=158,153,160,153) | 158 | 152 | 160 | 153 |
| Anti-14 pre (n=153,158,152,153) | 151 | 157 | 152 | 151 |
| Anti-14 post (n=158,153,160,153) | 158 | 153 | 160 | 153 |
| Anti-18C pre (n=151,153,145,151) | 149 | 151 | 145 | 151 |
| Anti-18C post (n=157,152,160,152) | 157 | 152 | 160 | 152 |
| Anti-19F pre (n=143,146,139,150) | 143 | 146 | 139 | 143 |
| Anti-19F post (n=158,151,160,152) | 158 | 151 | 160 | 152 |
| Anti-23F pre (n=152,156,150,153) | 149 | 153 | 144 | 141 |
| Anti-23F post (n=158,153,160,153) | 158 | 152 | 158 | 153 |
Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Opsono-1 pre (n=144,145,141,143) | 46 | 39 | 41 | 8 |
| Opsono-1 post (n=140,139,140,137) | 132 | 133 | 127 | 12 |
| Opsono-4 pre (n=104,121,112,109) | 61 | 67 | 61 | 73 |
| Opsono-4 post (n=137,134,140,135) | 137 | 134 | 140 | 135 |
| Opsono-5 pre (n=116,114,117,124) | 77 | 71 | 72 | 3 |
| Opsono-5 post (n=124,130,136,127) | 121 | 127 | 131 | 4 |
| Opsono-6B pre (n=133,132,133,137) | 75 | 60 | 75 | 67 |
| Opsono-6B post (n=142,135,142,140) | 134 | 127 | 135 | 138 |
| Opsono-7F pre (n=111,122,115,104) | 109 | 117 | 109 | 42 |
| Opsono-7F post (n=140,137,139,112) | 140 | 137 | 139 | 53 |
| Opsono-9V pre (n=133,133,130,130) | 131 | 130 | 122 | 126 |
| Opsono-9V post (n=143,139,143,137) | 143 | 139 | 143 | 137 |
| Opsono-14 pre (n=121,125,114,125) | 115 | 116 | 107 | 124 |
| Opsono-14 post (n=137,138,138,134) | 137 | 138 | 138 | 134 |
| Opsono-18C pre (n=126,118,123,123) | 45 | 54 | 34 | 35 |
| Opsono-18C post (n=121,129,121,114) | 121 | 127 | 121 | 110 |
| Opsono-19F pre (n=127,135,134,134) | 102 | 110 | 95 | 29 |
| Opsono-19F post (n=137,137,139,133) | 133 | 132 | 139 | 131 |
| Opsono-23F pre (n=132,136,128,137) | 121 | 120 | 105 | 124 |
| Opsono-23F post (n=145,143,146,143) | 145 | 143 | 146 | 143 |
Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Anti-6A pre (n=145,144,144,149) | 126 | 120 | 119 | 110 |
| Anti-6A post (n=156,152,159,152) | 152 | 145 | 149 | 148 |
| Anti-19A pre (n=145,153,145,151) | 130 | 138 | 121 | 87 |
| Anti-19A post (n=157,153,160,152) | 154 | 151 | 155 | 149 |
Anti-pneumococcal antibody cut-off value assessed was ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Opsono-6A pre (n=108,110,106,110) | 68 | 66 | 73 | 62 |
| Opsono-6A post (n=127,128,128,122) | 116 | 119 | 117 | 119 |
| Opsono-19A pre (n=133,138,136,134) | 4 | 11 | 4 | 2 |
| Opsono-19A post (n=124,132,130,123) | 77 | 75 | 50 | 29 |
Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Pre (n=147,153,147,146) | 144 | 147 | 138 | 59 |
| Post (n=158,152,160,148) | 158 | 151 | 160 | 66 |
Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Pre (n=68,65,66,78) | 57 | 62 | 62 | 68 |
| Post (n=89,84,79,76) | 89 | 84 | 79 | 76 |
Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Pre (n=126,124,125,135) | 95 | 82 | 105 | 102 |
| Post (n=156,149,159,149) | 156 | 149 | 159 | 149 |
Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.
| subjects | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Pre (n=147,144,150,148) | 122 | 128 | 145 | 143 |
| Post (n=157,153,160,152) | 157 | 153 | 160 | 152 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | — | — | 297/359 (82.7%) |
| GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | — | — | 303/363 (83.5%) |
| GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | — | — | 302/358 (84.4%) |
| Prevenar™ + Menitorix™ | — | — | 287/357 (80.4%) |
| Event | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| Gastroenteritis rotavirusGastrointestinal disorders | 4/359 | 0/363 | 1/358 | 0/357 |
| GastroenteritisInfections and infestations | 2/359 | 4/363 | 2/358 | 3/357 |
| PneumoniaInfections and infestations | 2/359 | 1/363 | 0/358 | 3/357 |
| Febrile convulsionNervous system disorders | 0/359 | 1/363 | 2/358 | 2/357 |
| BronchopneumoniaInfections and infestations | 1/359 | 1/363 | 0/358 | 2/357 |
| DiarrhoeaGastrointestinal disorders | 0/359 | 0/363 | 0/358 | 2/357 |
| PharyngitisInfections and infestations | 0/359 | 1/363 | 2/358 | 0/357 |
| Thermal burnInjury, poisoning and procedural complications | 2/359 | 0/363 | 1/358 | 0/357 |
| BronchitisInfections and infestations | 1/359 | 0/363 | 1/358 | 1/357 |
| ConcussionInjury, poisoning and procedural complications | 0/359 | 0/363 | 0/358 | 1/357 |
| Event | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ |
|---|---|---|---|---|
| PainGeneral disorders | 196/359 | 195/363 | 193/358 | 165/357 |
| RednessGeneral disorders | 194/359 | 183/363 | 186/358 | 173/357 |
| IrritabilityGeneral disorders | 170/359 | 190/363 | 191/358 | 157/357 |
| SwellingGeneral disorders | 162/359 | 148/363 | 150/358 | 134/357 |
| DrowsinessGeneral disorders | 124/359 | 142/363 | 139/358 | 105/357 |
| FeverGeneral disorders | 109/359 | 122/363 | 105/358 | 108/357 |
| Loss of appetiteGeneral disorders | 101/359 | 99/363 | 112/358 | 93/357 |
| Upper respiratory tract infectionInfections and infestations | 6/359 | 19/363 | 14/358 | 18/357 |
| Age, Continuous(Months) | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ | Total |
|---|---|---|---|---|---|
| Mean | 14.3 ± 1.81 | 14.3 ± 1.74 | 14.3 ± 1.78 | 14.3 ± 1.78 | 14.3 ± 1.78 |
| Sex: Female, Male(Participants) | GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™ | GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™ | Prevenar™ + Menitorix™ | Total |
|---|---|---|---|---|---|
| Female | 182 | 176 | 195 | 171 | 724 |
| Male | 177 | 187 | 163 | 186 | 713 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Apr 2007 to primary completion in Jan 2008, 8 months.
Results were first posted in Aug 2009, 1 year 6 months after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 8 months is below that.
Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PHiD-CV vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Pediarix